Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johanna Oechtering

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Annals of Neurology|March 16, 2022
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MSJohanna Oechtering, Therese Lincke, Sabine Schaedelin, et al.
Brain : a Journal of Neurology|September 24, 2025
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosisRoberto Furlan, Sabine Schaedelin, Jette Lautrup Frederiksen, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Trials|September 11, 2024
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trialPerrine Janiaud, Chiara Zecca, Anke Salmen, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 14, 2024
Complement Activation Is Associated With Disease Severity in Multiple SclerosisJohanna Oechtering, Kerstin Stein, Sabine A Schaedelin, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Nature Communications|November 9, 2022
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional studyManina M Etter, Tomás A Martins, Laila Kulsvehagen, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Annals of Neurology|March 16, 2022
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MSJohanna Oechtering, Therese Lincke, Sabine Schaedelin, et al.
Brain : a Journal of Neurology|September 24, 2025
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosisRoberto Furlan, Sabine Schaedelin, Jette Lautrup Frederiksen, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Trials|September 11, 2024
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trialPerrine Janiaud, Chiara Zecca, Anke Salmen, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 14, 2024
Complement Activation Is Associated With Disease Severity in Multiple SclerosisJohanna Oechtering, Kerstin Stein, Sabine A Schaedelin, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Nature Communications|November 9, 2022
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional studyManina M Etter, Tomás A Martins, Laila Kulsvehagen, et al.
Pageof 6